Forward Pharma A/S (FWP): Price and Financial Metrics

Forward Pharma A/S (FWP)

Today's Latest Price: $6.55 USD

0.01 (0.15%)

Updated Jan 25 6:55pm

Add FWP to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

FWP Stock Price Chart Interactive Chart >

Price chart for FWP

FWP Price/Volume Stats

Current price $6.55 52-week high $12.72
Prev. close $6.54 52-week low $4.61
Day low $6.52 Volume 12,900
Day high $6.66 Avg. volume 33,760
50-day MA $7.03 Dividend yield N/A
200-day MA $6.57 Market Cap 44.47M

Forward Pharma A/S (FWP) Company Bio

Forward Pharma A/S is a Danish biopharmaceutical company developing FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications. The company was founded in 2005 and is based in Copenhagen, Denmark.

FWP Latest News Stream

Event/Time News Detail
Loading, please wait...

FWP Latest Social Stream

Loading social stream, please wait...

View Full FWP Social Stream

Latest FWP News From Around the Web

Below are the latest news stories about Forward Pharma A that investors may wish to consider to help them evaluate FWP as an investment opportunity.

Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 Restrictions

COPENHAGEN, Denmark, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to ongoing precautionary measures against the spread of the novel coronavirus (“COVID-19”), the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) again has rescheduled the oral hearing of the appeal against the decision of the Opposition Division that revoked the EP2801355 patent (the “’355 Patent”). The new hearing date is set for September 6, 2021.About Forward Pharma: Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license...

Yahoo | January 12, 2021

A Trio of Stock Picks for the Short-Term Investor

These companies are trading below the liquidation value Continue reading...

Yahoo | July 14, 2020

Forward Pharma Announces New Date for the EP2801355 Appeal Hearing due to COVID-19

On January 29, 2018, the Opposition Division of the EPO concluded the oral proceedings concerning the ‘355 Patent (the “Opposition Proceeding”). The Opposition Division revoked the ‘355 Patent after considering oppositions from several opponents. On March 22, 2018, the Opposition Division issued its detailed reasons for the decision.

Yahoo | May 12, 2020

Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2019

COPENHAGEN, Denmark, April 24, 2020 -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported.

Yahoo | April 24, 2020

Forward Pharma A/S Announces Change in Ratio of American Depositary Shares to Ordinary Shares

COPENHAGEN, Denmark, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that its Board of…

GlobeNewswire | November 26, 2019

Read More 'FWP' Stories Here

FWP Price Returns

1-mo N/A
3-mo 1.24%
6-mo -1.15%
1-year 0.31%
3-year -82.54%
5-year -68.08%
YTD -6.83%
2020 8.41%
2019 18.77%
2018 -78.80%
2017 34.09%
2016 -21.05%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9665 seconds.